Equity Profile

NKTR

Nektar Therapeutics

Health CarePharmaceuticals$1.9B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:15 PM EDT

Nektar Therapeutics Misses on EPS, Stock Down 2.02%

Metric	Actual	Expected	Surprise
EPS	$-1.82	$-1.60	-4.60%
Revenue	—	$11M	—

management commentary, guidance changes, and full analysis available with Pro.

Nektar Therapeutics Misses on EPS, Stock Down 2.02%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.82	$-1.60	-4.60%
Revenue	—	$11M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.02% decline in the stock price following the earnings announcement. The company did not provide revenue figures, and there was no guidance update, leaving investors uncertain about future performance. The stock's reaction reflects concerns over the company's financial health and outlook.

Company Snapshot

Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, it operates in the health care sector, addressing significant medical needs through its research and development efforts.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.60

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$11M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In the last quarter, Nektar reported an EPS of $-1.78, which was better than analysts' expectations of $-2.76, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting Nektar to report a loss of $1.60 per share on revenues of $11 million this quarter. The market is closely watching how the company performs against these expectations.

Bull Case

If Nektar can exceed revenue expectations and show signs of improving its financial performance, it could lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or lower revenue, it could raise concerns about its financial viability and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$-1.60

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$11M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue for this quarter, and how does it compare to the $11 million consensus?

Revenue figures will be crucial in assessing the company's market performance and growth potential.

Will the EPS come in better than the consensus estimate of $-1.60?

A smaller loss than expected could indicate improving financial health and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Nektar's potential for revenue growth due to recent positive surprises in EPS, which could indicate stronger underlying demand for its products.

Supporting Evidence

Nektar has consistently surprised on EPS, with a 63% beat rate in the last 8 quarters.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the pharmaceutical sector indicate a potential uptick in demand for innovative therapies.

Key Risk

If the revenue exceeds $11 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Nektar to improve its financial performance against the backdrop of previous earnings surprises.

Bull Confirmed If

Reporting revenue above $11 million with an EPS better than $-1.60 would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.60 and revenue below $6 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.50%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a potential move of about 5.5% in either direction following the earnings report.

Options are pricing ±8.2% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.7%

Calls (60K)P/C Ratio: 0.25Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests a positive stock reaction, with an average 1-day move of +1.25%.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

If the company misses expectations, history suggests a potential downside move of around +0.54%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Details on sales performance and market demand for existing therapies.
3Management's outlook on future revenue growth and profitability.
4Insights into cost management and operational efficiency improvements.
5Responses to competitive pressures in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

APLEReported

Apple Hospitality REIT, Inc.

RecapView

May4

CRBGReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.60

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$11M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting Nektar to report a loss of $1.60 per share on revenues of $11 million this quarter. The market is closely watching how the company performs against these expectations.

Bull Case

If Nektar can exceed revenue expectations and show signs of improving its financial performance, it could lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or lower revenue, it could raise concerns about its financial viability and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$-1.60

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$11M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue for this quarter, and how does it compare to the $11 million consensus?

Revenue figures will be crucial in assessing the company's market performance and growth potential.

Will the EPS come in better than the consensus estimate of $-1.60?

A smaller loss than expected could indicate improving financial health and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Nektar's potential for revenue growth due to recent positive surprises in EPS, which could indicate stronger underlying demand for its products.

Supporting Evidence

Nektar has consistently surprised on EPS, with a 63% beat rate in the last 8 quarters.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the pharmaceutical sector indicate a potential uptick in demand for innovative therapies.

Key Risk

If the revenue exceeds $11 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Nektar to improve its financial performance against the backdrop of previous earnings surprises.

Bull Confirmed If

Reporting revenue above $11 million with an EPS better than $-1.60 would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.60 and revenue below $6 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.50%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a potential move of about 5.5% in either direction following the earnings report.

Options are pricing ±8.2% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.7%

Calls (60K)P/C Ratio: 0.25Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests a positive stock reaction, with an average 1-day move of +1.25%.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

If the company misses expectations, history suggests a potential downside move of around +0.54%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Details on sales performance and market demand for existing therapies.
3Management's outlook on future revenue growth and profitability.
4Insights into cost management and operational efficiency improvements.
5Responses to competitive pressures in the pharmaceutical market.